Abstract
Group B streptococcus (GBS) can cause significant maternal and neonatal morbidity. Over the past 30 years, reductions in early-onset GBS neonatal sepsis in the United States have been attributable to the guidelines from the Centers for Disease Control and Prevention for antepartum screening and treating this organism during labor. This article highlights the clinical implications, screening, diagnosis, prophylactic interventions, and future therapies for mothers with GBS during the peripartum period.
Keywords:
Diagnosis; Group B streptococcus; Intrapartum prophylaxis; Neonate; Pregnancy; Screening.
Copyright © 2014 Elsevier Inc. All rights reserved.
MeSH terms
-
Adult
-
Anti-Bacterial Agents / administration & dosage*
-
Antibiotic Prophylaxis / methods*
-
Drug Administration Schedule
-
Female
-
Humans
-
Infant, Newborn
-
Infant, Newborn, Diseases / epidemiology
-
Infant, Newborn, Diseases / microbiology*
-
Infectious Disease Transmission, Vertical / prevention & control*
-
Practice Guidelines as Topic
-
Pregnancy
-
Pregnancy Complications, Infectious / epidemiology
-
Pregnancy Complications, Infectious / microbiology*
-
Pregnancy Complications, Infectious / prevention & control
-
Premature Birth
-
Prenatal Diagnosis
-
Risk Factors
-
Sepsis / epidemiology
-
Sepsis / microbiology*
-
Sepsis / prevention & control
-
Streptococcal Infections / epidemiology
-
Streptococcal Infections / microbiology*
-
Streptococcal Infections / prevention & control
-
Streptococcal Vaccines
-
United States / epidemiology
Substances
-
Anti-Bacterial Agents
-
Streptococcal Vaccines